🇯🇵·3d agoCDMO
Announcement of Termination of Co-Promotion of Rituxan ® in Japan (Anti-CD20 Monoclonal Antibody)
Publisher
C
Chugai Pharmaceutical
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on chugai-pharm.co.jp
Leave the platform to read the original full article on the publisher site.
Source: Chugai Pharmaceutical
Scope: CDMO
Related coverage
More related coverage
Natco Pharma·1d ago
Pharma Research & Development
Pharma Research & Development
IIT Delhi Biosciences·1d ago
Latest Research
IIT Delhi Biosciences·1d ago
Geliose Mobility, an IIT Delhi incubated startup, launches ‘HOPE’, an affordable electric scooter for last mile delivery and personal commute
The Lancet·1d ago